Tag: ipilimumab

1. Adding sargramostim to ipilimumab for advanced melanoma resulted in improvement in overall survival and fewer adverse events when compared to ipilimumab alone. 2. Adding sargramostim to ipilimumab for advanced melanoma demonstrated no improvement in progression free survival. Evidence Rating Level: 2 (Good)        Study Rundown: Melanoma is a leading cause of...
Image: PD In this section, we will highlight the key high-impact studies, updates, and analyses published in medicine during the past week. Geographic Variation in Cardiovascular Procedure Use Among Medicare Fee-for-Service vs Medicare Advantage Beneficiaries  In this retrospective analysis of patients in capitated and fee-for-service Medicare plans, investigators found the capitated Medicare...
Image: PD              1. Combination therapy of nivolumab and ipilimumab achieved rapid and deep tumor regression in a subset of metastatic melanoma patients. 2. The therapy is associated with significant side effects that are comparable to monotherapies. Evidence Rating Level: 2 (Good)  Study Rundown: This study suggests that...